CN104968686B - 趋化素-细胞素融合蛋白和其应用 - Google Patents

趋化素-细胞素融合蛋白和其应用 Download PDF

Info

Publication number
CN104968686B
CN104968686B CN201280077622.3A CN201280077622A CN104968686B CN 104968686 B CN104968686 B CN 104968686B CN 201280077622 A CN201280077622 A CN 201280077622A CN 104968686 B CN104968686 B CN 104968686B
Authority
CN
China
Prior art keywords
leu
lys
ser
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280077622.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104968686A (zh
Inventor
邱绣河
周宽基
沈瑞鸿
范怡馨
林佩桦
吴佩珊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xue Fusheng
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN104968686A publication Critical patent/CN104968686A/zh
Application granted granted Critical
Publication of CN104968686B publication Critical patent/CN104968686B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201280077622.3A 2012-12-05 2012-12-05 趋化素-细胞素融合蛋白和其应用 Active CN104968686B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/001629 WO2014085947A1 (zh) 2012-12-05 2012-12-05 趋化素-细胞素融合蛋白和其应用

Publications (2)

Publication Number Publication Date
CN104968686A CN104968686A (zh) 2015-10-07
CN104968686B true CN104968686B (zh) 2020-02-04

Family

ID=50882722

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280077622.3A Active CN104968686B (zh) 2012-12-05 2012-12-05 趋化素-细胞素融合蛋白和其应用

Country Status (7)

Country Link
US (4) US20150307577A1 (enExample)
EP (1) EP2930189B1 (enExample)
JP (1) JP6174710B2 (enExample)
CN (1) CN104968686B (enExample)
AU (1) AU2012396113B2 (enExample)
CA (1) CA2893981C (enExample)
WO (1) WO2014085947A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3972992A4 (en) 2019-05-20 2023-07-19 Pandion Operations, Inc. MADCAM TARGETED IMMUNOTLERANCE
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
TW202309270A (zh) * 2021-04-19 2023-03-01 美商步行魚醫療公司 用於細胞療法的ｂ細胞擴增之方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1382158A (zh) * 1999-08-09 2002-11-27 利思进药品公司 多细胞因子－抗体复合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2322687A1 (en) * 1999-10-29 2001-04-29 Regents Of The University Of California Compositions containing c-terminal polypeptides of angiogenic chemokines and methods of use
WO2001040311A1 (fr) * 1999-11-30 2001-06-07 Shionogi & Co., Ltd. Proteine fusionnee de chimiokine slc-il2
US20050053579A1 (en) * 2001-10-23 2005-03-10 Jacques Galipeau Novel synthetic chimeric fusion transgene with immuno-therapeutic uses
US20050287118A1 (en) * 2003-11-26 2005-12-29 Epitomics, Inc. Bacterial plasmid with immunological adjuvant function and uses thereof
CN101445560A (zh) * 2008-12-31 2009-06-03 河南省生物工程技术研究中心 一种畜禽用融合蛋白的制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1382158A (zh) * 1999-08-09 2002-11-27 利思进药品公司 多细胞因子－抗体复合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
IL-12基因联合CD40L基因治疗小鼠黑色素瘤的实验研究;张建华;《中国免疫学杂志》;20071231;第23卷;摘要 *
MIP-2γ/GM-CSF融合蛋白的构建、表达及其双重生物学功能的初步研究;张意等;《中国肿瘤生物治疗杂志》;20040430;第11卷(第2期);第133-137页 *
mSDF-1γ/GM-CS融合蛋白的制备及其对辐射小鼠造血损伤恢复的促进;徐斌等;《中国肿瘤生物治疗杂志》;20091231;第16卷(第1期);第24-28页 *
SDF-1γ/ rhGM-CSF 融合蛋白的制备及其趋化作用;居小萍等;《中国肿瘤生物治疗杂志》;20110830;第18卷(第4期);第2.4节、图4 *
融合基因CCL21-CD40L对结肠癌主动免疫的诱导;宫婷;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20091215;第3.7节、图20、图21，第46页最后一段 *

Also Published As

Publication number Publication date
CN104968686A (zh) 2015-10-07
JP6174710B2 (ja) 2017-08-02
CA2893981A1 (en) 2014-06-12
AU2012396113A1 (en) 2015-07-02
US20170327554A1 (en) 2017-11-16
US20150307577A1 (en) 2015-10-29
EP2930189B1 (en) 2020-04-29
WO2014085947A1 (zh) 2014-06-12
US20190270788A1 (en) 2019-09-05
US10336801B2 (en) 2019-07-02
JP2016503434A (ja) 2016-02-04
EP2930189A1 (en) 2015-10-14
CA2893981C (en) 2021-11-16
US20230265150A1 (en) 2023-08-24
EP2930189A4 (en) 2016-06-08
AU2012396113B2 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
CN104968686B (zh) 趋化素-细胞素融合蛋白和其应用
Yin et al. Carp interleukin-1beta in the role of an immuno-adjuvant
KR102322510B1 (ko) 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
US20070160578A1 (en) Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
KR100862136B1 (ko) 인터루킨-18 변이체, 이들의 생산 및 용도
EP0753066A1 (en) Recombinant bcg vaccines
AU758576B2 (en) Chemokines with amino-terminal modifications
Sanchez et al. Expression of inducible CC chemokines in rainbow trout (Oncorhynchus mykiss) in response to a viral haemorrhagic septicemia virus (VHSV) DNA vaccine and interleukin 8
WO2005090400A1 (en) Immunosuppressive cytokine
TWI487713B (zh) 趨化素－細胞素融合蛋白和其應用
CN114044805B (zh) 一类促进猪机体产生广谱性免疫应答的多肽及其应用
CN113896771B (zh) 一类促进猪机体产生非洲猪瘟病毒抗原特异性免疫应答的多肽及其应用
CN114315962B (zh) 一类促进猪机体产生非洲猪瘟病毒抗原特异性免疫应答的多肽及其应用
CN113956330B (zh) 一类促进猪机体产生广谱性免疫应答的多肽及其应用
CN114044806B (zh) 一类促进猪机体产生广谱性免疫应答的多肽及其应用
WO2014172805A1 (zh) 具有增进的细胞素活性的组合物和其应用
TW201441250A (zh) 具有增進的細胞素活性的組合物和其應用
Aru sion in of i
WO2004038002A2 (en) Modulation of dendritic cell function and other cellular responses mediated by defensin compositions
CN112209992A (zh) 一类促进猪机体产生非洲猪瘟病毒抗原特异性免疫应答的多肽及其应用
Dechamma Certificate
Li et al. The immunoregulation of mice by somatic transgenic expression of porcine interleukin-6 gene and CpG sequence
Vior et al. The involvement of chemokines to normal and pathological immune responses.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20151116

Address after: Taiwan Guoguang Chinese Taichung City Road No. 250

Applicant after: Xue Fusheng

Address before: Taichung City, Taiwan, China

Applicant before: Qiu Xiuhe

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant